• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病基因检测的经济学

Economics of Genetic Testing for Diabetes.

机构信息

The University of Chicago Medicine, 5841 S Maryland Ave, MC 5053, Chicago, IL, 60637, USA.

出版信息

Curr Diab Rep. 2019 Mar 27;19(5):23. doi: 10.1007/s11892-019-1140-7.

DOI:10.1007/s11892-019-1140-7
PMID:30919097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6886700/
Abstract

PURPOSE OF REVIEW

Monogenic diabetes is an uncommon but important form of diabetes, with the most common causes benefitting from management that accounts for the genetic mutation. This often results in decreased costs and treatment burden for affected individuals. Misdiagnosis as type 1 and type 2 diabetes is common. Given the significant burden of diabetes costs to the healthcare system, it is important to assess the economic impact of incorporating genetic testing for monogenic diabetes into clinical care through formal cost-effectiveness analyses (CEAs). This article briefly summarizes the barriers to timely monogenic diabetes diagnosis and then summarizes findings from CEAs on genetic testing for monogenic diabetes.

RECENT FINDINGS

CEAs have shown that routine genetic testing of all patients with a clinical diagnosis of type 1 diabetes can be cost-saving when applied to the scenarios of neonatal diabetes or in a pediatric population. Routine screening has not been shown to be cost-effective in adult populations. However, next-generation sequencing strategies and applying biomarkers to identify and limit genetic testing to people most likely to have monogenic diabetes are promising ways to make testing strategies cost-effective. CEAs have shown that genetic testing for monogenic diabetes diagnosis can be cost-effective or cost-saving and should guide insurers to consider broader coverage of these tests, which would lead to accurate and timely diagnosis and impact treatment and clinical outcomes.

摘要

目的综述

单基因糖尿病是一种罕见但重要的糖尿病形式,最常见的病因受益于针对基因突变的管理,这通常会降低受影响个体的成本和治疗负担。误诊为 1 型和 2 型糖尿病很常见。鉴于糖尿病给医疗保健系统带来的巨大负担,通过正式的成本效益分析(CEA)评估将单基因糖尿病基因检测纳入临床护理的经济影响非常重要。本文简要总结了及时诊断单基因糖尿病的障碍,然后总结了关于单基因糖尿病基因检测的 CEA 研究结果。

最近的发现

CEA 研究表明,对所有临床诊断为 1 型糖尿病的患者进行常规基因检测,如果应用于新生儿糖尿病或儿科人群,可以节省成本。常规筛查在成年人群中并未显示出成本效益。然而,下一代测序策略和应用生物标志物来识别并将基因检测限制在最有可能患有单基因糖尿病的人群中,是使检测策略具有成本效益的有希望的方法。CEA 研究表明,单基因糖尿病诊断的基因检测具有成本效益或可以节省成本,这应该促使保险公司考虑更广泛地覆盖这些检测,从而实现准确和及时的诊断,并影响治疗和临床结果。

相似文献

1
Economics of Genetic Testing for Diabetes.糖尿病基因检测的经济学
Curr Diab Rep. 2019 Mar 27;19(5):23. doi: 10.1007/s11892-019-1140-7.
2
Systematic genetic testing for recessively inherited monogenic diabetes: a cross-sectional study in paediatric diabetes clinics.系统遗传性隐性单基因糖尿病基因检测:儿科糖尿病临床的横断面研究。
Diabetologia. 2022 Feb;65(2):336-342. doi: 10.1007/s00125-021-05597-y. Epub 2021 Oct 23.
3
How do I diagnose Maturity Onset Diabetes of the Young in my patients?我如何诊断我的患者是否患有青年发病的成年型糖尿病?
Clin Endocrinol (Oxf). 2022 Oct;97(4):436-447. doi: 10.1111/cen.14744. Epub 2022 May 2.
4
Review of current status of molecular diagnosis and characterization of monogenic diabetes mellitus: a focus on next-generation sequencing.单基因糖尿病分子诊断和特征的现状综述:下一代测序的重点。
Expert Rev Mol Diagn. 2020 Apr;20(4):413-420. doi: 10.1080/14737159.2020.1730179. Epub 2020 Mar 1.
5
Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach.单基因糖尿病的表型异质性:基于基因panel的下一代测序方法的临床及诊断效用
Mol Genet Metab. 2014 Dec;113(4):315-320. doi: 10.1016/j.ymgme.2014.09.007. Epub 2014 Sep 28.
6
Genetic testing for monogenic diabetes using targeted next-generation sequencing in patients with maturity-onset diabetes of the young.在青少年成年起病型糖尿病患者中使用靶向新一代测序技术进行单基因糖尿病的基因检测。
Pol Arch Med Wewn. 2015;125(11):845-51. doi: 10.20452/pamw.3164. Epub 2015 Nov 9.
7
Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register.在芬兰儿科糖尿病登记处,超过 10%的诊断时未检出 1 型糖尿病相关自身抗体的儿童中鉴定出单基因变异。
Diabetologia. 2023 Mar;66(3):438-449. doi: 10.1007/s00125-022-05834-y. Epub 2022 Nov 23.
8
Identification of monogenic diabetes in an Australian cohort using the Exeter maturity-onset diabetes of the young (MODY) probability calculator and next-generation sequencing gene panel testing.使用埃克塞特青少年起病的成年型糖尿病(MODY)可能性计算器和下一代测序基因 panel 检测鉴定澳大利亚队列中的单基因糖尿病。
Acta Diabetol. 2024 Feb;61(2):181-188. doi: 10.1007/s00592-023-02193-x. Epub 2023 Oct 9.
9
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing.生物标志物筛查和级联遗传检测对 MODY 基因检测成本效益的影响。
Diabetes Care. 2019 Dec;42(12):2247-2255. doi: 10.2337/dc19-0486. Epub 2019 Sep 26.
10
Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.基于人群的生物标志物筛查途径评估,以辅助诊断青年发病患者的单基因糖尿病。
Diabetes Care. 2017 Aug;40(8):1017-1025. doi: 10.2337/dc17-0224.

引用本文的文献

1
Genetics Evaluation Outcomes From an Academic Multidisciplinary Atypical Diabetes Program.来自学术性多学科非典型糖尿病项目的遗传学评估结果
J Endocr Soc. 2025 Jun 5;9(8):bvaf091. doi: 10.1210/jendso/bvaf091. eCollection 2025 Aug.
2
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country.在糖尿病中实施基因检测:发展中国家医疗保健专业人员的知识、认知及障碍
Popul Med. 2024 Mar;6. doi: 10.18332/popmed/184210.
3
A Review of the Biosynthesis and Structural Implications of Insulin Gene Mutations Linked to Human Disease.胰岛素基因突变与人类疾病相关的综述:生物合成与结构影响
Cells. 2023 Mar 25;12(7):1008. doi: 10.3390/cells12071008.
4
Co-segregation analysis and functional trial in vivo of candidate genes for monogenic diabetes.单基因糖尿病候选基因的共分离分析及体内功能试验。
BMJ Open Diabetes Res Care. 2022 Dec;10(6). doi: 10.1136/bmjdrc-2022-003038.
5
Prevalence and clinical characteristics of T2DM patients with OTUD3 gene rs78466831 SNP at a single academic center in China.在中国的一家学术中心,T2DM 患者 OTUD3 基因 rs78466831 SNP 的患病率和临床特征。
Front Endocrinol (Lausanne). 2022 Dec 2;13:1059641. doi: 10.3389/fendo.2022.1059641. eCollection 2022.
6
Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register.在芬兰儿科糖尿病登记处,超过 10%的诊断时未检出 1 型糖尿病相关自身抗体的儿童中鉴定出单基因变异。
Diabetologia. 2023 Mar;66(3):438-449. doi: 10.1007/s00125-022-05834-y. Epub 2022 Nov 23.
7
Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans.多基因自身免疫性疾病风险等位基因在小鼠和人类的共享分子网络中协同作用,影响 B 细胞耐受。
Front Immunol. 2022 Aug 24;13:953439. doi: 10.3389/fimmu.2022.953439. eCollection 2022.
8
MODY probability calculator utility in individuals' selection for genetic testing: Its accuracy and performance.MODY 可能性计算器工具在个体遗传检测选择中的应用:其准确性和性能。
Endocrinol Diabetes Metab. 2022 Sep;5(5):e00332. doi: 10.1002/edm2.332. Epub 2022 Jul 12.
9
Pathogenic variants of MODY-genes in adult patients with early-onset type 2 diabetes.早发型2型糖尿病成年患者中MODY基因的致病变异
Acta Diabetol. 2022 May;59(5):747-750. doi: 10.1007/s00592-021-01847-y. Epub 2022 Feb 3.
10
Genetic Spectrum of Neonatal Diabetes.新生儿糖尿病的基因谱
Balkan J Med Genet. 2021 Mar 23;23(2):5-15. doi: 10.2478/bjmg-2020-0027. eCollection 2020 Nov.

本文引用的文献

1
Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.基于大规模平行测序的青少年发病的成年型糖尿病常规筛查的成本效果分析:降低卫生系统成本和提高患者生活质量。
Diabetes Care. 2019 Jan;42(1):69-76. doi: 10.2337/dc18-0261. Epub 2018 Dec 6.
2
A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.一项英国全国性前瞻性研究显示,MODY 患者在停用胰岛素和二甲双胍后,治疗改变与遗传亚型和临床特征相关,可预测最佳血糖控制。
Diabetologia. 2018 Dec;61(12):2520-2527. doi: 10.1007/s00125-018-4728-6. Epub 2018 Sep 18.
3
Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial.超重和肥胖的 2 型糖尿病患儿中单基因糖尿病: TODAY 临床试验。
Genet Med. 2018 Jun;20(6):583-590. doi: 10.1038/gim.2017.150. Epub 2017 Oct 12.
4
Economic Costs of Diabetes in the U.S. in 2017.2017 年美国糖尿病的经济成本。
Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.
5
Congenital forms of diabetes: the beta-cell and beyond.先天性糖尿病:β细胞及其他。
Curr Opin Genet Dev. 2018 Jun;50:25-34. doi: 10.1016/j.gde.2018.01.005. Epub 2018 Feb 16.
6
Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore.新加坡基于算法的遗传检测与不检测青少年发病的成年型糖尿病(MODY)的增量成本效益。
J Med Genet. 2017 Nov;54(11):747-753. doi: 10.1136/jmedgenet-2017-104670. Epub 2017 Aug 23.
7
Transient Neonatal Diabetes Mellitus: A Challenge and Opportunity for Specialized Nursing Care.短暂性新生儿糖尿病:专科护理的挑战与机遇
Neonatal Netw. 2017 Jul 1;36(4):196-205. doi: 10.1891/0730-0832.36.4.196.
8
Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.基于人群的生物标志物筛查途径评估,以辅助诊断青年发病患者的单基因糖尿病。
Diabetes Care. 2017 Aug;40(8):1017-1025. doi: 10.2337/dc17-0224.
9
Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes.使用生物标志物和基因检测进行的系统人群筛查,在英国儿童糖尿病患者人群中识别出2.5%患有单基因糖尿病。
Diabetes Care. 2016 Nov;39(11):1879-1888. doi: 10.2337/dc16-0645. Epub 2016 Jun 6.
10
GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.美国单基因糖尿病登记处中的GCK-MODY:常被误诊且接受不必要的治疗。
Acta Diabetol. 2016 Oct;53(5):703-8. doi: 10.1007/s00592-016-0859-8. Epub 2016 Apr 22.